Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
复制标题
富含亮氨酸的α -2糖蛋白是监测接受阿达木单抗治疗的炎症性肠病疾病活动性的潜在生物标志物：PLANET研究
DOI：
10.1007/s00535-021-01793-0
复制
发表时间：
2021-06
影响因子：
6.3
通讯作者：
Matsumoto T
中科院分区：
文献类型：
--
作者：
Shinzaki S;Matsuoka K;Tanaka H;Takeshima F;Kato S;Torisu T;Ohta Y;Watanabe K;Nakamura S;Yoshimura N;Kobayashi T;Shiotani A;Hirai F;Hiraoka S;Watanabe M;Matsuura M;Nishimoto S;Mizuno S;Iijima H;Takehara T;Naka T;Kanai T;Matsumoto T
这项多中心前瞻性研究（UMIN000019958）旨在评估血清富白细胞α -2糖蛋白（LRG）水平在监测炎症性肠病（IBD）疾病活动性中的作用。本研究纳入了接受阿达木单抗治疗的中度至重度IBD患者。在第0、12、24和52周检测血清LRG、c反应蛋白（CRP）和粪便钙保护蛋白（fCal）水平。溃疡性结肠炎（UC）患者在第0、12和52周进行结肠镜检查，克罗恩病（CD）患者在第0、24和52周进行结肠镜检查。使用克罗恩病简单内镜评分（SES-CD）和UC梅奥内镜评分（MES）评估内镜活动。共有81名患者入组。血清有水平下降以及改善临床和内窥镜结果在adalimumab治疗(27.4±12.6μg / ml周0,15.5±7.7μg / ml在第12周,15.7±9.6μg / ml 24周,和14.5±6.8μg / ml 52周),在每个时间点与内窥镜相关活动(SES-CD: r = 0.391周0,r = 0.563在24周,r = 0.697在52周,MES: r = 0.534 0周,12周后r = 0.429, r = 0.335在52周)。在所有时间点，内镜下活动与LRG的相关性优于CRP和fCal （SES-CD: LRG: r = 0.636, CRP: r = 0.402, fCal: r = 0.435; MES: LRG: r = 0.568, CRP: 0.389, fCal: r = 0.426）。血清LRG是阿达木单抗治疗期间CD和UC患者内镜下活动的有用生物标志物。在线版本包含补充材料，可在10.1007/s00535-021-01793-0获得。
This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD). Patients with moderate-to-severe IBD initiated on adalimumab therapy were enrolled herein. Serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCal) levels were measured at week 0, 12, 24, and 52. Colonoscopy was performed at week 0, 12, and 52 for ulcerative colitis (UC), and at week 0, 24, and 52 for Crohn’s disease (CD). Endoscopic activity was assessed using the Simple Endoscopic Score for Crohn’s Disease (SES-CD) for CD and the Mayo endoscopic subscore (MES) for UC. A total of 81 patients was enrolled. Serum LRG levels decreased along with improvements in clinical and endoscopic outcomes upon adalimumab treatment (27.4 ± 12.6 μg/ml at week 0, 15.5 ± 7.7 μg/ml at week 12, 15.7 ± 9.6 μg/ml at week 24, and 14.5 ± 6.8 μg/ml at week 52), being correlated with endoscopic activity at each time point (SES-CD: r = 0.391 at week 0, r = 0.563 at week 24, r = 0.697 at week 52; MES: r = 0.534 at week 0, r = 0.429 at week 12, r = 0.335 at week 52). Endoscopic activity better correlated with LRG compared to CRP and fCal on pooled analysis at all time points (SES-CD: LRG: r = 0.636, CRP: r = 0.402, fCal: r = 0.435; MES: LRG: r = 0.568, CRP: 0.389, fCal: r = 0.426). Serum LRG is a useful biomarker of endoscopic activity both in CD and UC during the adalimumab treatment. The online version contains supplementary material available at 10.1007/s00535-021-01793-0.
登录
查看更多内容
影响因子：
6.3
作者：
Matsuoka K;Kobayashi T;Ueno F;Matsui T;Hirai F;Inoue N;Kato J;Kobayashi K;Kobayashi K;Koganei K;Kunisaki R;Motoya S;Nagahori M;Nakase H;Omata F;Saruta M;Watanabe T;Tanaka T;Kanai T;Noguchi Y;Takahashi KI;Watanabe K;Hibi T;Suzuki Y;Watanabe M;Sugano K;Shimosegawa T
通讯作者：
Shimosegawa T
影响因子：
158.5
作者：
SCHROEDER, KW;TREMAINE, WJ;ILSTRUP, DM
通讯作者：
ILSTRUP, DM
影响因子：
4.9
作者：
Kawashima, Kousaku;Ishihara, Shunji;Kinoshita, Yoshikazu
通讯作者：
Kinoshita, Yoshikazu
影响因子：
168.9
作者：
Colombel, Jean-Frederic;Panaccione, Remo;D'Haens, Geert
通讯作者：
D'Haens, Geert
影响因子：
24.5
作者：
Satsangi, J.;Silverberg, M. S.;Colombel, J-F
通讯作者：
Colombel, J-F